NuVasive CEO Lukianov looks back, ahead
NuVasive chairman & CEO Alex Lukianov touts expectation-shattering preliminary figures for the company's 2012 sales and talks about integration and globalization as important drivers for the year ahead.
Medical device company NuVasive (NSDQ:NUVA) got a big boost this morning after releasing preliminary results for 2012, with a jocular chairman & CEO Alex Lukianov sharing some of the highlights with an audience at the J.P. Morgan healthcare conference in San Francisco.
NuVasive beat its own estimates for 2012 with full-year revenues of about $619 million, compared to previous guidance of $601-$606 million for the year.
That represents a 15% spike in growth over 2011 for NuVasive, which Lukianov variously referred to as a "market-maker," a "share-taker" and a "destructive force."